ZNF217 and breast carcinoma: In terms of predicting treatment response, retrospective analysis of two independent expression datasets from breast cancer patients who received neoadjuvant chemotherapy, showed lower levels of ZNF217 mRNA in responders compared to in non-responders (p = 0.04 and p < 0.0001) [30].